C4 Therapeutics (CCCC) Stock Forecast & Price Target

$3.73 -0.27 (-6.75%)

(As of 09:03 AM ET)

C4 Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
3

Buy
3

Based on 6 Wall Street analysts who have issued ratings for C4 Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for CCCC.

Consensus Price Target

$10.67
185.97% Upside

According to the 6 analysts' twelve-month price targets for C4 Therapeutics, the average price target is $10.67. The highest price target for CCCC is $20.00, while the lowest price target for CCCC is $4.00. The average price target represents a forecasted upside of 185.97% from the current price of $3.73.

Get the Latest News and Ratings for CCCC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for C4 Therapeutics and its competitors.

CCCC Analyst Ratings Over Time

Type	Current Forecast 12/31/23 to 12/30/24	1 Month Ago 12/1/23 to 11/30/24	3 Months Ago 10/2/23 to 10/1/24	1 Year Ago 12/31/22 to 12/31/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$10.67	$10.00	$9.29	$9.60
Forecasted Upside	185.97% Upside	119.78% Upside	67.01% Upside	69.91% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

Kamala’s final humiliation (Ad)

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

CCCC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CCCC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

C4 Therapeutics Stock vs. The Competition

Type	C4 Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	181.44% Upside	24,181.91% Upside	14.07% Upside
News Sentiment Rating	Positive News See Recent CCCC News	Positive News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $12.00	+228.77%
11/18/2024	Stephens 4 of 5 stars	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00	-7.19%
8/6/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+230.58%
5/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$13.00 ➝ $14.00	+111.16%
2/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$8.00	-17.10%
1/29/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral	$6.00	+9.69%
11/2/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$17.00 ➝ $7.00	+400.00%
10/9/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$5.00 ➝ $2.00	+16.96%
7/21/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$22.00 ➝ $20.00	+468.18%
5/30/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$10.00	+224.67%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Neutral	$12.00 ➝ $10.00	+80.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:43 AM ET.

CCCC Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for C4 Therapeutics is $10.67, with a high forecast of $20.00 and a low forecast of $4.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CCCC shares.
: According to analysts, C4 Therapeutics's stock has a predicted upside of 185.97% based on their 12-month stock forecasts.
: Over the previous 90 days, C4 Therapeutics's stock had 1 upgrade by analysts.
: C4 Therapeutics has been rated by research analysts at Stephens, and Wells Fargo & Company in the past 90 days.
: Analysts like C4 Therapeutics less than other "medical" companies. The consensus rating score for C4 Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CCCC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Kamala’s final humiliation (Ad)

It’s all waiting for you here.

This page (NASDAQ:CCCC) was last updated on 12/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Stock Forecast & Price Target